| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
Revenue  | 2,337 | 2,665 | 2,960 | 3,416 | 3,792 | 4,208 | 4,391 | 4,997 | 5,503 | 6,097 | 6,685 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,337 | 3,389 | 3,832 | 4,143 | 4,396 | 4,715 |
| EBITDA | 360 | 415 | 455 | 642 | 718 | 871 | 1,002 | 1,165 | 1,360 | 1,701 | 1,970 |
| Operating Profit % | 13 % | 14 % | 14 % | 16 % | 16 % | 18 % | 21 % | 22 % | 23 % | 25 % | 26 % |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 |
| Interest | 1 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 12 |
| Profit Before Tax | 344 | 398 | 437 | 622 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 |
| Tax | 115 | 143 | 160 | 220 | 249 | 210 | 235 | 281 | 324 | 417 | 470 |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 |
| EPS in ₹ | 107.75 | 120.12 | 130.19 | 188.81 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.60 |
Abbott
30,560.00
+230.00
(0.76%)
There are 5 new updates from the company23 hours ago
Show All
Market Cap
64,449.10 Cr
EPS
565.30
PE Ratio
48.36
Dividend Yield
1.35 %
Industry
Healthcare52 Week High
31,898.95
52 Week Low
25,325.00
PB Ratio
18.33
Debt to Equity
0.03
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from5 analysts
Company News
View All News
Abbott India Ltd: Q4 Profit and Revenue Surge, Stock ClimbsToday
Abbott India Ltd reported a 14.7% increase in Q4 net profit to Rs 359 crore, surpassing estimates. Revenue rose 9% to Rs 1,633 crore, while EBITDA grew 15% to Rs 439 crore. The company's stock price gained nearly 4%, reaching Rs 31,500 per share.
Abbott India Reports Q4 Results and Recommends DividendToday
Abbott India has reported its quarterly results. The company's Q4 net profit increased to 3.7 billion rupees, up from 2.87 billion rupees year-over-year and 3.6 billion rupees quarter-over-quarter. Q4 revenue rose to 16 billion rupees from 14.39 billion rupees year-over-year. Additionally, the company has recommended a dividend of 475 rupees per equity share.
Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed22 hours ago
Abbott India reported a 27.9% YoY increase in Q4 net profit to ₹367 crore. Revenue grew 11.5% to ₹1,604.6 crore. EBITDA rose 30% with margin expanding to 26.7%. The board recommended a final dividend of ₹475 per share for FY25, subject to shareholder approval.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,734.90 | #1 4,17,508.30 | 35.39 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 47.70 | |
6,279.50 | 1,64,975.40 | 79.75 | 8,184.00 | 0.89 | 1,600 | 64.53 | 62.83 | |
1,499.90 | 1,21,319.90 | 23.01 | 26,520.70 | 14.17 | 4,155 | 30.28 | 49.42 | |
3,266.80 | 1,10,502.40 | 59.35 | 10,785.70 | 11.59 | 1,656 | 13.54 | 52.85 | |
2,572.70 | 1,05,616.00 | 51.74 | 10,615.60 | 19.57 | 1,942 | -16.38 | 59.84 | |
1,230.70 | 1,03,163.70 | #1 18.22 | 28,905.40 | 12.36 | 5,578 | 21.14 | 64.04 | |
2,068.40 | 94,636.40 | 28.82 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 52.76 | |
902.70 | 91,034.00 | 20.07 | 19,831.50 | 13.82 | 3,831 | 29.92 | 56.61 | |
1,201.20 | 70,677.70 | 20.05 | 29,559.20 | 17.55 | 3,169 | -10.04 | 51.74 | |
30,560.00 | #10 64,449.10 | #7 48.36 | #10 6,097.20 | #9 10.80 | #10 1,201 | #5 27.83 | 54.55 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
10.80 %
Net Income Growth
26.52 %
Cash Flow Change
35.75 %
ROE
9.07 %
ROCE
9.92 %
EBITDA Margin (Avg.)
12.91 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 |
| Fixed Assets | 96 | 109 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 |
| Current Assets | 1,226 | 1,451 | 1,893 | 2,266 | 2,761 | 3,205 | 3,487 | 3,853 | 3,025 | 3,246 |
| Capital Work in Progress | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,953 | 4,315 | 4,958 |
| Total Liabilities | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 |
| Current Liabilities | 397 | 382 | 632 | 668 | 857 | 891 | 1,031 | 1,203 | 1,206 | 1,343 |
| Non Current Liabilities | 39 | 39 | 47 | 55 | 75 | 224 | 207 | 201 | 161 | 152 |
| Total Equity | 938 | 1,196 | 1,387 | 1,693 | 2,009 | 2,432 | 2,602 | 2,820 | 3,189 | 3,699 |
| Reserve & Surplus | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 |
| Investing Activities | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 |
| Operating Activities | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 |
| Financing Activities | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.18 % | 0.18 % | 0.18 % | 0.16 % | 0.16 % | 0.16 % |
| DIIs | 4.60 % | 5.80 % | 4.30 % | 4.20 % | 4.96 % | 5.24 % | 7.73 % | 8.39 % | 8.62 % | 8.67 % | 8.71 % | 8.74 % | 8.91 % | 8.81 % | 8.99 % | 9.01 % | 8.92 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.15 % | 15.83 % | 15.60 % | 15.81 % | 15.15 % | 14.72 % | 14.60 % | 14.25 % | 14.07 % | 13.95 % | 13.89 % | 13.97 % | 13.80 % | 13.86 % | 13.65 % | 13.59 % | 13.66 % |
| Others | 4.26 % | 3.38 % | 5.11 % | 5.01 % | 4.91 % | 5.06 % | 2.68 % | 2.37 % | 2.32 % | 2.39 % | 2.42 % | 2.13 % | 2.12 % | 2.16 % | 2.21 % | 2.25 % | 2.28 % |
| No of Share Holders | 0 | 84,478 | 75,540 | 73,417 | 83,236 | 90,567 | 82,113 | 83,526 | 72,086 | 69,582 | 68,885 | 72,252 | 69,382 | 71,588 | 69,449 | 67,892 | 69,934 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 40 | 55 | 65 | 250 | 275 | 275 | 325 | 410 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.75 | 0.42 | 1.67 | 1.55 | 1.26 | 1.2 | 1.33 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 15 May 2025 |  Quarterly Result Announcement | NA | 15 May 2025 | 30,145.75 | 30,348.45 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 26,518.15 | 26,142.55 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 28,526.15 | 29,115.20 |
| 08 Aug 2024 |  Annual General Meeting | NA | 08 Aug 2024 | 25,945.60 | 28,136.85 |
| 19 Jul 2024 |  Dividend | ₹ 410.00 /share | 19 Jul 2024 | 25,945.60 | 28,795.65 |
| 21 Jul 2023 | Dividend | ₹ 145.00 /share | 21 Jul 2023 | 20,970.55 | 23,665.10 |
| 21 Jul 2023 | Dividend | ₹ 180.00 /share | 21 Jul 2023 | 20,970.55 | 23,665.10 |
| 04 Aug 2022 | Dividend | ₹ 130.00 /share | 02 Aug 2022 | 16,529.20 | 20,621.45 |
| 04 Aug 2022 | Dividend | ₹ 145.00 /share | 02 Aug 2022 | 16,529.20 | 20,621.45 |
| 21 Jul 2021 | Dividend | ₹ 155.00 /share | 19 Jul 2021 | 16,224.75 | 17,427.95 |
| 21 Jul 2021 | Dividend | ₹ 120.00 /share | 19 Jul 2021 | 16,224.75 | 17,427.95 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 hours ago
2 hours agoRecord Date For Entitlement Of Dividend23 hours ago
23 hours agoAnnual General Meeting On August 13 202523 hours ago
23 hours agoAnnouncement under Regulation 30 (LODR)-Dividend Updates23 hours ago
23 hours agoResults For The Financial Year Ended March 31 202523 hours ago
23 hours agoBoard Meeting Outcome for Outcome Of Board Meeting1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Change in Management9 days ago
9 days agoBoard Meeting Intimation for Intimation Under Regulation 29 (1) (A) And (E) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.9 days ago
9 days agoAnnouncement Under Regulation 30.Apr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Apr 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Rumour verification - Regulation 30(11)Mar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 20, 2025
Feb 20, 2025Integrated Filing (Financial)Feb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Feb 06, 2025Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Feb 05, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Feb 03, 2025Board Meeting Intimation for Intimation Of Board Meeting Scheduled On February 5 2025 For Considering Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024.Jan 28, 2025
Jan 28, 2025Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Jan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 21, 2025
Jan 21, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 16, 2025
Jan 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2025
Jan 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 03, 2025
Jan 03, 2025Closure of Trading WindowDec 23, 2024
Dec 23, 2024Announcement under Regulation 30 (LODR)-Resignation of DirectorDec 16, 2024
Dec 16, 2024Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Dec 16, 2024
Dec 16, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Dec 13, 2024Abbott Launches 14 Valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection For Children Against Pneumococcal Bacterial Infections.Nov 28, 2024
Nov 28, 2024Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 28, 2024
Nov 28, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Nov 14, 2024Intimation Under Regulation 30 Of The Securities And Exchange Board Of India ( Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 14, 2024
Nov 14, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 12, 2024
Nov 12, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 08, 2024
Nov 08, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Nov 08, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Nov 07, 2024Related Party Transaction Statement For The Half Year Ended September 30, 2024Nov 07, 2024
Nov 07, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateNov 07, 2024
Nov 07, 2024Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024
Nov 07, 2024Board Meeting Outcome for Outcome Of Board MeetingNov 07, 2024
Nov 07, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 05, 2024
Nov 05, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 31, 2024
Oct 31, 2024Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 28, 2024
Oct 28, 2024Technical Indicators
RSI(14)
Neutral 51.70
ATR(14)
Volatile 726.20
STOCH(9,6)
Neutral 48.09
STOCH RSI(14)
Neutral 56.53
MACD(12,26)
Bearish -3.70
ADX(14)
Weak Trend 10.93
UO(9)
Bearish 39.54
ROC(12)
Uptrend But Slowing Down 0.76
WillR(14)
Neutral -57.07
About Abbott
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Website
Chairperson NameMunir Shaikh
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
